A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours.

被引：0
|
作者：
Shaw, H.
Plummer, R.
Vidal, L.
Perrett, R.
Pilkington, M.
Temple, G.
Fong, P.
Amelsberg, A.
Calvert, H.
De Bono, J.
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[3] Boehringer Ingelheim, Bracknell, Berks, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：127S / 127S
页数：1
相关论文
共 50 条
  • [1] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.
    Agus, D. B.
    Terlizzi, E.
    Stopfer, P.
    Amelsberg, A.
    Gordon, M. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
  • [2] A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors.
    Plummer, R
    Vidal, L
    Perrett, R
    Shaw, H
    Pilkington, M
    Hanwell, J
    Temple, G
    Fong, P
    Amelsberg, A
    Calvert, H
    de Bono, J
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8990S - 8990S
  • [3] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Marshall, JL
    Lewis, NL
    Amelsberg, A
    Briscoe, J
    Hwang, J
    Malik, S
    Cohen, R
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9072S - 9072S
  • [4] Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Vidal, Laura
    Adam, Jan
    Stephens, Peter
    Spicer, James
    Shaw, Heather
    Ang, Jooern
    Temple, Graham
    Bell, Susan
    Shahidi, Mehdi
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Futreal, Andrew
    Calvert, Hilary
    de Bono, Johann S.
    Plummer, Ruth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3965 - 3972
  • [5] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Lewis, N.
    Marshall, J.
    Amelsberg, A.
    Cohen, R. B.
    Stopfer, P.
    Hwang, J.
    Malik, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 143S - 143S
  • [6] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    Eskens, Falm
    Mom, C. H.
    Planting, A. S. T.
    Gietema, J. A.
    Amelsberg, A.
    Huisman, H.
    van Doorn, L.
    Burger, H.
    Stopfer, P.
    Verweij, J.
    de Vries, Ege
    [J]. BRITISH JOURNAL OF CANCER, 2008, 98 (01) : 80 - 85
  • [7] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.
    Solca, F
    Baum, A
    Guth, B
    Colbatzky, F
    Blech, S
    Amelsberg, A
    Himmelsbach, F
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [8] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    F A L M Eskens
    C H Mom
    A S T Planting
    J A Gietema
    A Amelsberg
    H Huisman
    L van Doorn
    H Burger
    P Stopfer
    J Verweij
    E G E de Vries
    [J]. British Journal of Cancer, 2008, 98 : 80 - 85
  • [9] Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents
    Solca, F.
    Baum, A.
    Himmelsbach, F.
    Amelsberg, A.
    Adolf, G.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 172
  • [10] Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
    Stopfer, P
    Schaefer, HG
    Amelsberg, A
    Huisman, H
    Eskens, F
    Gietema, JA
    Briscoe, J
    Lewis, N
    Cohen, RB
    Marshall, J
    Verweij, J
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9075S - 9075S
12345